Are treatment sequences, adverse events, long-term disease progression adequately considered in cost-effectiveness analyses of rheumatoid arthritis ?: A critical economic litterature review

Abstract

costs at one year from ID were € 5'480, 39% RA-related (€ 682 for drugs and 1'444 for hospitalisations), € 1'345 for ambulatory care, € 1'016 for other drugs and € 994 for other hospitalisations. ConClusions: Treatment patterns of RA patients in Italy are heterogeneous, with a variety of strategy options reported. More than half of healthcare costs in RA patients are not disease-related, suggesting that management of comorbidities is a cost-driver.